The Global Livestock Therapeutics & Vaccines Market was valued at USD 18.2 billion in 2025 and is estimated to grow at a CAGR of 5.6% to reach USD 31.5 billion by 2035.
Growth in the livestock therapeutics & vaccines market is driven by the increasing occurrence of infectious illnesses, parasitic conditions, and production-related health challenges affecting livestock populations worldwide. Rising demand for effective disease prevention and treatment solutions has encouraged continuous innovation across veterinary pharmaceuticals and animal health technologies. Advancements in biologics, vaccine development, veterinary therapeutics, diagnostic capabilities, precision animal healthcare, and modern livestock management systems are improving disease prevention, treatment efficiency, and overall herd health. At the same time, improvements in formulation technologies and preventive healthcare approaches are helping livestock producers enhance treatment compliance while reducing operational challenges. Greater adoption of digital animal health management, precision farming practices, and advanced breeding programs is strengthening disease surveillance and supporting more proactive livestock healthcare strategies. Continued investments in innovative veterinary medicines, preventive healthcare products, and next-generation biologics are expected to sustain market expansion throughout the forecast period. In addition, increasing commercial livestock production, higher spending on veterinary healthcare, expanding animal disease control initiatives, and growing awareness of responsible antimicrobial use continue to reinforce long-term growth across the global livestock therapeutics & vaccines market.
The therapeutics segment generated USD 11.1 billion in 2025. Strong demand for veterinary treatment products continues to support segment growth as livestock producers increasingly focus on maintaining herd health, improving productivity, reducing mortality, and minimizing economic losses. The expanding adoption of veterinary pharmaceuticals across commercial livestock production systems continues to strengthen the market position of the therapeutics segment throughout the forecast period.
The bacterial diseases segment was valued at USD 4.7 billion in 2025. Increasing disease prevalence across livestock populations continues to support demand for veterinary medicines, preventive vaccines, and diagnostic solutions designed to improve animal health outcomes. At the same time, greater emphasis on responsible antimicrobial use is encouraging the development of safer, more targeted treatment options while strengthening disease management practices across the livestock industry.
North America Livestock Therapeutics & Vaccines Market accounted for 40% share in 2025 and is anticipated to grow at a CAGR of 5.3% through 2035. Regional growth is supported by a well-established animal healthcare ecosystem, extensive commercial livestock production, and favorable regulatory initiatives focused on disease prevention and animal health management. Continued investment in veterinary research, innovative biologics, advanced vaccines, and therapeutic products is expected to further strengthen market expansion across the region.
Major companies operating in the global livestock therapeutics & vaccines market include Zoetis, Merck Animal Health (MSD Animal Health), Boehringer Ingelheim Animal Health, Elanco Animal Health, Ceva Santé Animale, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, Indian Immunologicals, Vaxxinova, Biogénesis Bagó, Bioveta, Neogen Corporation, and Norbrook. Companies operating in the livestock therapeutics & vaccines market are strengthening their market position by expanding research and development activities, enhancing biologics and vaccine portfolios, and introducing advanced veterinary therapeutics that improve disease prevention and treatment outcomes. Many manufacturers are increasing investments in innovative production technologies, expanding manufacturing capacity, and improving product quality to address growing global demand. Strategic collaborations, acquisitions, licensing agreements, and distribution partnerships continue to support geographic expansion and broaden customer reach.
This product will be delivered within 2-4 business days.
Growth in the livestock therapeutics & vaccines market is driven by the increasing occurrence of infectious illnesses, parasitic conditions, and production-related health challenges affecting livestock populations worldwide. Rising demand for effective disease prevention and treatment solutions has encouraged continuous innovation across veterinary pharmaceuticals and animal health technologies. Advancements in biologics, vaccine development, veterinary therapeutics, diagnostic capabilities, precision animal healthcare, and modern livestock management systems are improving disease prevention, treatment efficiency, and overall herd health. At the same time, improvements in formulation technologies and preventive healthcare approaches are helping livestock producers enhance treatment compliance while reducing operational challenges. Greater adoption of digital animal health management, precision farming practices, and advanced breeding programs is strengthening disease surveillance and supporting more proactive livestock healthcare strategies. Continued investments in innovative veterinary medicines, preventive healthcare products, and next-generation biologics are expected to sustain market expansion throughout the forecast period. In addition, increasing commercial livestock production, higher spending on veterinary healthcare, expanding animal disease control initiatives, and growing awareness of responsible antimicrobial use continue to reinforce long-term growth across the global livestock therapeutics & vaccines market.
The therapeutics segment generated USD 11.1 billion in 2025. Strong demand for veterinary treatment products continues to support segment growth as livestock producers increasingly focus on maintaining herd health, improving productivity, reducing mortality, and minimizing economic losses. The expanding adoption of veterinary pharmaceuticals across commercial livestock production systems continues to strengthen the market position of the therapeutics segment throughout the forecast period.
The bacterial diseases segment was valued at USD 4.7 billion in 2025. Increasing disease prevalence across livestock populations continues to support demand for veterinary medicines, preventive vaccines, and diagnostic solutions designed to improve animal health outcomes. At the same time, greater emphasis on responsible antimicrobial use is encouraging the development of safer, more targeted treatment options while strengthening disease management practices across the livestock industry.
North America Livestock Therapeutics & Vaccines Market accounted for 40% share in 2025 and is anticipated to grow at a CAGR of 5.3% through 2035. Regional growth is supported by a well-established animal healthcare ecosystem, extensive commercial livestock production, and favorable regulatory initiatives focused on disease prevention and animal health management. Continued investment in veterinary research, innovative biologics, advanced vaccines, and therapeutic products is expected to further strengthen market expansion across the region.
Major companies operating in the global livestock therapeutics & vaccines market include Zoetis, Merck Animal Health (MSD Animal Health), Boehringer Ingelheim Animal Health, Elanco Animal Health, Ceva Santé Animale, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, Indian Immunologicals, Vaxxinova, Biogénesis Bagó, Bioveta, Neogen Corporation, and Norbrook. Companies operating in the livestock therapeutics & vaccines market are strengthening their market position by expanding research and development activities, enhancing biologics and vaccine portfolios, and introducing advanced veterinary therapeutics that improve disease prevention and treatment outcomes. Many manufacturers are increasing investments in innovative production technologies, expanding manufacturing capacity, and improving product quality to address growing global demand. Strategic collaborations, acquisitions, licensing agreements, and distribution partnerships continue to support geographic expansion and broaden customer reach.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Animal Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Disease Indication, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Distribution Channel, 2022-2035 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
- Zoetis
- Merck Animal Health (MSD Animal Health)
- Boehringer Ingelheim Animal Health
- Elanco Animal Health
- Ceva Santé Animale
- Virbac
- HIPRA
- Vetoquinol
- Phibro Animal Health
- Indian Immunologicals
- Vaxxinova
- Biogénesis Bagó
- Bioveta
- Neogen Corporation
- Norbrook
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 18.2 Billion |
| Forecasted Market Value ( USD | $ 31.5 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
